APC & VLE Therapeutics have been named BioPharma Company of the Year, recognising The Medicine Accelerator’s Irish-led approach to process science, digital CMC, and GMP-ready medicine development.

FDA’s 2025 approvals show biologics growing more complex. Learn why next-gen modalities demand stronger analytics, process design, and integrated CMC strategies.

Small molecules still dominate FDA approvals, but rising stereochemical and solid-state complexity demands stronger CMC strategies for 2026 readiness.

The Medicine Accelerator joined Ireland's first Manufacturing Day on October 3rd, opening its doors to students and showcasing digital pharmaceutical manufacturing careers.

Building on this foundation, APC announces a strategic partnership with METTLER TOLEDO AutoChem, a global leader in automated reactor technology, process analytical tools (PAT), and chemical development software platforms. Together, the partnership seeks to build a fully integrated digital development environment—advancing how data, decisions, and design converge across the full CMC lifecycle.

The Medicine Accelerator is expanding its iAchieve® digital CMC platform business unit with senior leadership and product roles to drive global pharma digital transformation.

iAchieve® now integrates large language models and agentic AI to deliver natural language CMC querying, risk forecasting, and streamlined tech transfer across 35+ active programmes.

Avoid FDA Complete Response Letters (CRLs) by focusing on a strong CMC strategy, deep process understanding, and scientific excellence to ensure smoother drug approvals.

The Medicine Accelerator proudly announces its triple win at the 2024 Pharma Industry Awards, securing Biotech Company of the Year, Pharma Company of the Year - SME, and Pharma Industry Company of the Year. Shortlisted in eight categories, APC and VLE stood out for their excellence in scientific innovation, operational performance, sustainability, and talent development.